Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Exenatide

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

AstraZeneca · Phase 3 · Terminated · Enrollment 13

NCT03419624

ArmPopulationDoseWeeksEstimandWeight change
Dapagliflozin plus ExenatideObesity + T2Dn/rn/rn/rn/r
Placebo plus PlaceboObesity + T2Dn/rn/rn/rn/r
Placebo plus ExenatideObesity + T2Dn/rn/rn/rn/r